Clinical Trial Update: Safety and Efficacy of SOF/VEL/VOX FDC for 8 Weeks and SOF/VEL for 12 Weeks in Adults Chronic Genotype 3 HCV Infection and Cirrhosis [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating eight weeks of SOF/VEL/VOX fixed-dose combination or twelve weeks of SOF/VEL in adults with chronic genotype 3 hepatitis C infection an…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cirrhosis
• Hepatitis C

Drugs mentioned

• SOF/VEL (Sofosbuvir/Velpatasvir)
• SOF/VEL/VOX (sofosbuvir/velpatasvir/voxilaprevir)

Snippet

Sponsor: Gilead Sciences | Conditions: Hepatitis C Virus Infection | Phase 3 | Status: COMPLETED | Results posted: 2017-11-14